8 Quotes by Catherine Arnold

Lilly's current valuation still provides an attractive entry point. The stock trades at a modest 8% to 10% premium to its peers against 2006 and 2007 earnings and at a discount against our 2008 to 2010 forecast.

We just can't get there. Maybe they see something we don't see.

We think the downside risk here is modest. Merck has fundamental challenges ahead based on its base business. We really concluded the stock is trading incorporating these items.

Schering-Plough shares are most likely to be impacted by first quarter 2006 results.

After a long product portfolio transition, we forecast that Bristol-Myers could return to a period of sustained high teens earnings per share growth in 2007-2010.

This is half the savings that Pfizer achieved with its recently announced program.

The U.S. case is more important because of the economic implications. It (the U.K. ruling) is a nice psychological boost but you can't extrapolate the U.S. ruling from this because of the different legal standards.

The U.S. case is more important because of the economic implications, ... a nice psychological boost but you can't extrapolate the U.S. ruling from this because of the different legal standards.